AUS
NZ
UK
CA
USA
IND
Highlights
- Policlinico Casilino becomes the first site in Italy to adopt Imricor’s iCMR ablation solutions.
- Imricor now has 15 sites across the European region.
- Additional sites are advancing well to begin real-time iCMR guided ablations with Imricor’s products.
- Imricor has partnered with a world-class firm to access defibrillator for its planned ventricular tachycardia ablation clinical trial.
Shares of Imricor Medical Systems, Inc. (ASX:IMR) are riding high on the ASX charts today following a crucial update. IMR shares jumped by over 4.6% to AU$0.680 at AEDT 12:30 PM after the innovative MRI-compatible medical devices developer announced its first site in Italy.
Imricor is a worldwide leader in real-time iCMR cardiac ablation products and is headquartered in the US. It is the only company in the world that can provide iCMR ablation equipment and catheters.
First Imricor iCMR ablation solutions site in Italy
Policlinico Casilino in Rome, Italy, adopted the company’s iCMR ablation solutions, bringing the total number of Imricor sites in Europe to 15. This is the company’s first site in Italy.
The company has signed a pricing agreement with Policlinico Casilino that sets the pricing for its products and has a preliminary term of one year.
The agreement is a remarkable strategic goal of Imricor for expanding the number of sites performing real-time iCMR cardiac ablation procedures in Europe. Planning is underway to start operations in the second quarter of 2022.
Additional Imricor sites making headway
Switzerland-based Lausanne University Hospital (CHUV) has started constructing an iCMR lab, likely to be a research and training centre of excellence. The lab would enable physicians to learn iCMR ablation techniques.
The hospital is consulting with Imricor on the design specifics.
In Germany, construction of another iCMR lab is on the cards. This lab is expected to be operational in the fourth quarter of 2022.
Do read: From IMC to ALA: Healthcare stocks with best YTD returns
Imricor gearing up to provide MRI-compatible equipment for VT
Ventricular Tachycardia (VT) is a problem with the heart rhythm (arrhythmias). Imricor’s next step is to market its products for the treatment of VT.
The company recently signed a development agreement with Mammendorfer Institut Für
Physik Und Medizin GmbH (MIPM). The Germany-based company is an established manufacturer of MRI-compatible monitoring equipment and has recently developed an MRI-compatible defibrillator in consultation with Imricor.
Imricor will collaborate with the firm for product development and clinical trials, including the upcoming VT trial. MIPM will provide its defibrillator for the trial, the last piece of equipment and critical for real-time iCMR ablations of VT.
Also read: How have REG, CSL share prices fared after budget’s healthcare boost?
